Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 25 or more amino acid residues in defined sequence
Patent
1996-12-23
1999-12-28
Mertz, Prema
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
25 or more amino acid residues in defined sequence
530402, 5303881, 5303873, 53038815, 5303871, 530351, 4353201, 435325, C07K 1455, C07K 1618, C12N 510
Patent
active
060083190
ABSTRACT:
A novel permeability enhancing peptide (PEP) is a fragment of interleukin-2. When joined to a delivery vehicle that can target a tumor site, the PEP can increase the subsequent uptake of antineoplastic or tumor imaging agents. The PEP can be chemically joined to a monoclonal antibody to form an immunoconjugate. Alternatively, an expression vector is genetically engineered to express a fusion protein. The fusion protein has an antigen-binding portion joined to the PEP. The PEP is most effective when it takes the form of a dimer, linked by a disulfide bridge. The PEP is substantially free of cytokine activity and produces minimal toxic side effects on normal tissues.
REFERENCES:
patent: Re33653 (1991-07-01), Mark et al.
patent: 4518584 (1985-05-01), Mark et al.
patent: 4738927 (1988-04-01), Taniguchi et al.
patent: 4780313 (1988-10-01), Koichiro et al.
patent: 4832940 (1989-05-01), Ege
patent: 4894227 (1990-01-01), Stevens et al.
Ahmad, A., et al., "Recombinant targeted proteins for biotherapy", Mol. Biother., 2:67-73 (1990).
Antoni, G., et al., "A Short Syntetic Peptide Fragment of Human Interleukin 1 With Immunostimulatory But Not Inglammatory Activity", J. Immunol., 137:3201-3204 (1986).
Bazan, J.F., "Unraveling the Structure of IL-2", Science, 257:410-412 (1992).
Cohen, F.E., et al., "Structure-Activity Studies of Interleukin-2", Science, 234:349-352 (1986).
Epstein, A.L., et al., Two New Monoclonal Antibodies, Lym-1 and Lym-2, Reactive with Human B-Lymphocytes ands Derived Tumors, with Immunodiagnostic and Immunotherapeutic Potential, Cancer Res., 47:830-840 (1987).
Epstein, A.L., et al., "A Novel Method for the Detection of Necrotic Lesions in Human Cancers", Cancer Res., 48:5842-5848 (1988).
Epstein, A.L., et al., "Identification of a Monoclonal Antibody, TV-1, Directed against the Basement Membrane of Tumor Vessels, and Its Use to Enhance the Delivery of Macromolecules to Tumors after Conjugation with Interleukin 2", Cancer Res., 55:2673-2680 (1995).
Epstein, A.L., "Tumor Necrosis Imaging and Treatment of Solid Tumors," pp. 259-288 in Handbook of Targeted Delivery of Imaging Agents, V.P. Torchilin, Ed.,CRC Press (1995).
Epstein, A.L., "New Approaches to Improved Antibody Targeting," pp. 516-533 in Nuclear Medicine, vol. 1, R.E. Henkin, Ed., Mosby-Year Book (1996).
Gillies, S.D., et al., "Expression of Genetically Engineered Immunoconjugates of Lymphotoxin and a Chimeric Anti-Ganglioside GD2 Antibody", Hybridoma, 10:347-355 (1991).
Gillies, S.D., et al., "Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells", Proc. Natl. Acad. Sci., USA, 89:1428-1432 (1992).
Hu, P., et al., "A human-mouse chimeric Lym-1 monoclonal antibody with specificity for human lymphomas expressed in a baculovirus system", Hum. Antibod. Hybridomas 6(1):57-67 (1995).
Imler, J.-L., et al., "Identification of three adjacent amino acids of interleukin-2 receptor .beta. chain which control the affinity and the specificity of the interaction with interleukin-2", The EMBO Journal, 11:2047-2053 (1992).
Kaplan, D., et al., "Self-association of interleukin-2 bound to its receptor", The FASEB Journal, 9:1096-1102 (1995).
Khawli, L.A., et al., "Effect of Seven New Vasoactive Immunoconjugates on the Enhancement of Monoclonal Antibody Uptake in Tumors", Cancer, 73:824-831 (1994).
Kiyokawa, T., et al., "Protein engineering of diptheria-toxin, related interleukin-2 fusion toxins to increase cytotoxic potency for high-affinity IL-2-receptor-bearing target cells", Protein Engineering, 4:463-468 (1991).
Landgraf, B.E., et al., "Recombinant Interleukin-2 Analogs", J. Biol. Chem., 267:18511-18519 (1992).
Landolfi, N.F., "A Chimeric IL-2/Ig Molecule Possesses The Functional Activity of Both Proteins", J. Immunol., 146:915-919 (1991).
LeBerthon, B., et al., "Enhanced Tumor Uptake of Macromolecules Induced by a Novel Vasoactive Interleukin 2 Immunoconjugate", Cancer Res., 51:2694-2698 (1991).
LeMaistre, C.F., et al., "Phase I Trial of an Interleukin-2 (IL-2) Fusion Toxin (DAB.sub.486 IL-2) in Hematologic Malignancies Expressing the IL-2 Receptor", Blood, 79:2547-2554 (1992).
Lotze, M.T., "Interleukin-2", in Human Cytokines, Ed. by Aggarwal and Gutterman, pp. 81-96, (1992).
Marincola, F.M., "Interleukin-2", Biologic Therapy of Cancer Updates, 4(3):1-16 (1994).
McKay, D.B., "Unraveling the Structure of IL-2: Response", Science 257:412-413 (1992).
Naramura, M., et al., "Mechanisms of cellular cytotoxicity mediated by a recombinant antibody-IL2 fusion protein against human melanoma cells", Immunol. Lett., 39:91-99 (1994).
Savage, P., et al., "A recombinant single chain antibody interleukin-2 fusion protein", Br. J. Cancer, 67:304-310 (1993).
Taniguchi, T., et al., "Structure and expression of a cloned cDNA for human interleukin-2", Nature, 302:305-310 (1983).
Vuist, W.M.J., et al., "Two Distinct Mechanisms of Antitumor Activity Mediated by the Combination of Interleukin 2 and Monoclonal Antibodies", Cancer Res., 50:5767-5772 (1990).
Wang, A., et al., "Site-Specific Mutagenesis of the Human Interleukin-2 Gene: Structure-Function Analysis of the Cysteine Residues", Science, 224:1431-1433 (1984).
Epstein Alan L.
Khawli Leslie A.
Berliner Robert
Mertz Prema
University of Southern California
LandOfFree
Vasopermeability enhancing peptide of human interleukin-2 and im does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vasopermeability enhancing peptide of human interleukin-2 and im, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vasopermeability enhancing peptide of human interleukin-2 and im will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2383106